Patents Assigned to Ludwig Institute for Cancer Research
-
Patent number: 11013802Abstract: The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: GrantFiled: December 7, 2017Date of Patent: May 25, 2021Assignees: AGENUS INC., LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, MEMORIAL SLOAN KETTERING CANCER CENTERInventors: Marc van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, Nicholas Stuart Wilson, David Adam Savitsky, Mark Arthur Findeis, Dennis John Underwood, Jean-Marie Cuillerot, Igor Proscurshim, Olga Shebanova
-
Publication number: 20210113615Abstract: The invention relates to heterodimeric inactivatable chimeric antigen receptors (CARs) and their use for treatment.Type: ApplicationFiled: April 12, 2019Publication date: April 22, 2021Applicants: Ludwig Institute for Cancer Research Ltd., École Polytechnique Fédérale de LausanneInventors: George COUKOS, Melita IRVING, Bruno CORREIA, Pablo GAINZA-CIRAUQUI, Greta Maria Paola GIORDANO ATTIANESE
-
Patent number: 10947303Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-?1) are provided, particularly recognizing human and mouse TGF-?1 and not recognizing or binding TGF-?2 or TGF-?3. Particular antibodies are provided which specifically recognize and neutralize TGF-?1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.Type: GrantFiled: July 26, 2018Date of Patent: March 16, 2021Assignee: LUDWIG INSTITUTE FOR CANCER RESEARCH, LTD.Inventors: Jacques Van Snick, Catherine Uyttenhove, Thierry Boon
-
Patent number: 10912831Abstract: The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: GrantFiled: September 24, 2020Date of Patent: February 9, 2021Assignees: AGENUS INC., LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, MEMORIAL SLOAN KETTERING CANCER CENTERInventors: Marc van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, Nicholas Stuart Wilson, David Adam Savitsky, Mark Arthur Findeis, Dennis John Underwood, Jean-Marie Cuillerot, Igor Proscurshim, Olga Shebanova
-
Patent number: 10836830Abstract: The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.Type: GrantFiled: June 19, 2020Date of Patent: November 17, 2020Assignees: AGENUS INC., MEMORIAL SLOAN-KETTERING CANCER CENTER, LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.Inventors: Nicholas S. Wilson, Jeremy D. Waight, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Ekaterina V. Breous-Nystrom, Volker Seibert, Takemasa Tsuji, Olivier Léger, Dennis J. Underwood, Marc Van Dijk
-
Patent number: 10829559Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.Type: GrantFiled: March 15, 2019Date of Patent: November 10, 2020Assignees: Agenus Inc., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.Inventors: Volker Seibert, Olivier Léger, Marc Van Dijk, Taha Merghoub, David Schaer, Gerd Ritter, Takemasa Tsuji
-
Publication number: 20200338125Abstract: The invention relates to a method for expanding antigen-specific lymphocytes by culturing samples from a subject containing lymphocytes or lymphocytes derived from the sample in the presence of one or more peptides comprising antigens and/or in the presence of an antigen presenting cell presenting antigens. Also disclosed is the use of such method for improving personalized immunotherapy (e.g., tumor immunotherapy).Type: ApplicationFiled: November 6, 2018Publication date: October 29, 2020Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTDInventors: Sara BOBISSE, Alexandre HARARI, George COUKOS
-
Patent number: 10800849Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.Type: GrantFiled: April 25, 2018Date of Patent: October 13, 2020Assignees: Agenus Inc., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.Inventors: Ana M. Gonzalez, Nicholas S. Wilson, Dennis J. Underwood, Volker Seibert, Olivier Léger, Marc Van Dijk, Roberta Zappasodi, Taha Merghoub, Jedd David Wolchok, David Schaer, Gerd Ritter, Takemasa Tsuji
-
Patent number: 10793861Abstract: The present invention relates to RNA-based methods for inhibiting the expression of the superoxide dismutase 1 (SOD-1) gene. Recombinant adeno-associated viruses of the invention deliver DNAs encoding RNAs that knock down the expression of SOD-1. The methods have application in the treatment of amyotrophic lateral sclerosis.Type: GrantFiled: July 20, 2018Date of Patent: October 6, 2020Assignees: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL, LUDWIG INSTITUTE FOR CANCER RESEARCHInventors: Brian K. Kaspar, Kevin Foust, Don W. Cleveland
-
Patent number: 10765648Abstract: Disclosed herein are ?-galactosylceramide (?-GalCer) analogs and compositions thereof, methods of activating invariant Natural Killer T (iNKT) cells using said analogs, methods of treating diseases by activating iNKT cells using said analogs, and combination therapy of said analogs.Type: GrantFiled: April 17, 2019Date of Patent: September 8, 2020Assignee: LUDWIG INSTITUTE FOR CANCER RESEARCHInventors: Vincenzo Cerundolo, Gurdyal S. Besra, Liam R. Cox
-
Patent number: 10752612Abstract: Provided herein, inter alia, are compounds and methods for inhibiting PLK4 and for treating cancer in a subject in need thereof.Type: GrantFiled: April 15, 2016Date of Patent: August 25, 2020Assignee: LUDWIG INSTITUTE FOR CANCER RESEARCH LTDInventors: Timothy Gahman, Andrew Shiau
-
Patent number: 10723793Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 3 (TGF-?3) are provided, particularly recognizing human and mouse TGF-?3, particularly antibodies and fragments that do not recognize or bind TGF-?1 or TGF-?2. Particular antibodies are provided which specifically recognize and neutralize TGF-?3. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?3, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?3 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof.Type: GrantFiled: June 10, 2016Date of Patent: July 28, 2020Assignee: Ludwig Institute for Cancer Research, Ltd.Inventors: Jacques Van Snick, Catherine Uyttenhove
-
Patent number: 10676527Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.Type: GrantFiled: February 12, 2018Date of Patent: June 9, 2020Assignees: Ludwig Institute for Cancer Research Ltd., The Regents of the University of Michigan, University of Maryland, BaltimoreInventors: Ulf Eriksson, Linda Fredriksson, Daniel Lawrence, Enming Su, Manuel Yepes, Dudley Strickland
-
Patent number: 10626181Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.Type: GrantFiled: April 15, 2019Date of Patent: April 21, 2020Assignees: AGENUS INC., MEMORIAL SLOAN-KETTERING CANCER CENTER, LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.Inventors: Marc Van Dijk, Ekaterina V. Breous-Nystrom, Volker Seibert, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Hao Tang, Taha Merghoub, David A. Savitsky, Jeremy Waight, Nicholas S. Wilson
-
Patent number: 10604579Abstract: The present invention relates to a protein binding to GARP in the presence of TGF-? and uses thereof.Type: GrantFiled: May 9, 2018Date of Patent: March 31, 2020Assignees: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, UNIVERSITÉ CATHOLIQUE DE LOUVAIN, argenx BVBAInventors: Sophie Lucas, Pierre Coulie, Julia Cuende Villasur, Laure Dumoutier, Jean-Christophe Renauld, Sebastian Van Der Woning, Michael Saunders, Hans De Haard, Gitte De Boeck
-
Patent number: 10577426Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.Type: GrantFiled: April 25, 2018Date of Patent: March 3, 2020Assignees: AGENUS INC., MEMORIAL SLOAN-KETTERING CANCER CENTER, LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.Inventors: Ana M. Gonzalez, Nicholas S. Wilson, Dennis J. Underwood, Volker Seibert, Olivier Léger, Marc Van Dijk, Roberta Zappasodi, Taha Merghoub, Jedd David Wolchok, David Schaer, Gerd Ritter, Takemasa Tsuji
-
Publication number: 20200002766Abstract: Disclosed are methods for sequencing immune cell receptor repertoires from immune cell populations, and kits containing primer mixtures for the sequencing of immune cell receptor repertoires.Type: ApplicationFiled: January 30, 2018Publication date: January 2, 2020Applicant: Ludwig Institute for Cancer Research LtdInventor: Raphael Genolet
-
Publication number: 20190382751Abstract: The present disclosure provides compounds comprising modified oligonucleotides for use in CRISPR. In certain embodiments, such modified oligonucleotides provide improved properties of crRNA.Type: ApplicationFiled: December 28, 2017Publication date: December 19, 2019Applicants: Ionis Pharmaceuticals, Inc., Ludwig Institute for Cancer ResearchInventors: Meghdad Radhar, Thazha P. Prakash, Eric E. Swayze, C. Frank Bennett, Moira A. McMahon
-
Patent number: 10508303Abstract: The present invention relates to methods for haplotype determination and, m particular, haplotype determination at the whole genome level as well as targeted haplotype determination.Type: GrantFiled: July 18, 2014Date of Patent: December 17, 2019Assignee: LUDWIG INSTITUTE FOR CANCER RESEARCH LTDInventors: Bing Ren, Siddarth Selvaraj, Jesse Dixon, Anthony Schmitt
-
Patent number: 10479833Abstract: The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: GrantFiled: October 19, 2018Date of Patent: November 19, 2019Assignees: AGENUS INC., LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, MEMORIAL SLOAN KETTERING CANCER CENTERInventors: Marc van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, David Adam Savitsky, Nicholas Stuart Wilson